Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents

Affiliations

¹ Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
² Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy.
³ Design and Analysis of Clinical Trials Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
⁴ National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
⁵ Laboratory of Virology, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), Rome, Italy.
⁶ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

Francesca R Mauro et al. Br J Haematol. 2023 May.

. 2023 May;201(3):564-567.

doi: 10.1111/bjh.18701. Epub 2023 Feb 22.

¹ Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
² Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy.
³ Design and Analysis of Clinical Trials Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
⁴ National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
⁵ Laboratory of Virology, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), Rome, Italy.
⁶ North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

No abstract available

References

1. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015; 30;126(5):573-81. https://doi.org/10.1182/blood-2015-03-567388
1. Scarfò L, Chatzikonstantinou T, Rigolin GM, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL and CLL campus. Leukemia. 2020;34(9):2354-63. https://doi.org/10.1038/s41375-020-0959-x
1. Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-43. https://doi.org/10.1182/blood.2020006965
1. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-73. https://doi.org/10.1182/blood.2021011568
1. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscularazd7442 (Tixagevimab cilgavimab) for prevention of covid-19. N Engl J Med. 2022;386(23):2188-200. https://doi.org/10.1056/NEJMoa2116620